107 results
Page 4 of 6
8-K
EX-99.1
x0eqxwn
18 Dec 20
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
6:30am
424B5
4fw2p5 rq
16 Dec 20
Prospectus supplement for primary offering
4:01pm
424B5
ayoj4zihere7d1kcg
14 Dec 20
Prospectus supplement for primary offering
4:48pm
S-3ASR
9e11avr40p kh1rv
14 Dec 20
Automatic shelf registration
4:02pm
8-K
qnrk5
14 Dec 20
Regulation FD Disclosure
7:30am
8-K
EX-99.1
guvh5s1j2 k7
14 Dec 20
Regulation FD Disclosure
7:30am
8-K
EX-99.2
nmsqf2c0 koz
14 Dec 20
Regulation FD Disclosure
7:30am
8-K
EX-99.1
yb1 pq1tzbl9n0tkvo0
5 Nov 20
Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:31am
8-K
6xlvfl
14 Oct 20
Other Events
7:00am
8-K
EX-99.1
imfdqjpzgwjkuchim6
4 Aug 20
Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update
4:47pm
8-K
qm0yjky
29 May 20
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader
7:06am
8-K
EX-99.1
gu80y ai93
29 May 20
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader
7:06am
8-K
EX-99.2
9a7cv3
29 May 20
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader
7:06am
8-K
xpdg11p51lw8cn exgn
14 May 20
Other Events
12:00am
8-K
EX-99.1
f0gkbzdhml85
28 Apr 20
Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update
4:59pm